Huge Boom Expected in Valuation of Global Protein Extracts from Single Cell Protein Sources Market till 2023

Soaring number of initiatives by governments and private organizations for creating awareness amongst the people about the health and environmental benefits of alternative protein sources is one of the major factors responsible for the rise in the demand for protein extracts from single cell protein sources across the world. For instance, Valensa International, which is a major producer of microalgae-based nutraceuticals launched an alliance with a U.S. based trade organization called Algae Biomass Organization (ABO) in 2017 in order to create awareness amongst the masses about the consumption of microalgae as an alternative protein source. 

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/protein-extracts-from-single-cell-protein-sources-market/report-sample

The surging population of livestock and cattle including sheep, goat, and buffalo, has boosted the production of animal feed, which has in turn, propelled the need for animal protein. As per the International Feed Industry Federation (IFIF), the total worldwide production of compound feed was recorded to be 1.0 billion tonnes in 2016. Therefore, it can be said that owing to the increasing production of compound feed, the production of protein from various alternative sources such as animals, microbes, and plants will also increase in future.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/send-enquiry?enquiry-url=protein-extracts-from-single-cell-protein-sources-market

Due to the above-mentioned factors, the revenue generated from the worldwide sales of protein extracts from single protein sources will increase from $5.3 billion to $8.7 billion from 2017 to 2023. Moreover, the global protein extracts from single cell protein sources market is predicted to advance at an 8.6% CAGR during the forecast period (2018–2023). There are various alternative sources of protein, such as yeast, fungi, bacteria, and algae. Amongst these, the utilization of algae-based protein sources is expected to record the fastest rise in the coming years. 

Therefore, it can be said with full surety that owing to the increasing consumption of protein by livestock, animals, and people and increasing awareness amongst the masses about alternative protein sources, the demand for protein extracts from single cell protein sources will boom in future.

Read More

How are Awareness Campaigns Driving Disposable Plastic Blood Bag Market?

Heart diseases kill 17.9 people each year, while 9.6 million die of cancer, says the World Health Organization (WHO). With these, the surgery and hospitalization rates are rapidly going up. One of the most basic things many such patients need is blood, which, being a highly critical and easily contaminable product, has to be kept in clean and sterile bags. Thus, with the growing incidence of chronic diseases and usage of blood at healthcare centers, the disposable plastic blood bag market is expanding around the world.

Receive Sample Copy of this Report:https://www.psmarketresearch.com/market-analysis/disposable-plastic-blood-bag-market/report-sample

Disposable bags are indispensable for two main reasons: to stop blood of different groups mixing with each other, which can be deadly for the recipient, and to minimize the chances of blood-borne diseases, such as acquired immune deficiency syndrome (AIDS). Disposable bags are also used when collecting blood, and with the rate of blood donation going up, the demand for such containers is also surging. For instance, in the U.K., the number of donated units increased from 161,019 in 2015/16 to 159.264 in 2018/19, according to the National Health Service (NHS) data.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/send-enquiry?enquiry-url=disposable-plastic-blood-bag-market

The primary reason behind the increase in blood donations is the continuous efforts by government and international organizations to raise the awareness about the same. Apart from the WHO, International Federation of Red Cross and Red Crescent Societies (IFRC) and American Red Cross are engaged in these activities. With campaigns and other activities organized by these agencies, people are realizing the importance of blood in patient treatment as well as the fact that donating blood regularly is good for their own health.

Across the world, the largest disposable plastic blood bag market is North America, majorly on account of the rising number of patients suffering from blood disorders. For instance, the Leukemia and Lymphoma Society says that every three minutes, blood cancer is diagnosed in one person in the U.S. Further, according to the National Cancer Institute of the U.S., 61,780 cases of leukemia were detected in the country and 2019, and the disease resulted in 22,840 deaths.

Hence, as the surgery and hospitalization rates increase and more people willingly donate blood, the demand for disposable plastic bags to store it will also rise.

Read More

Adrenocortical Carcinoma Therapeutics - Pipeline Analysis, Collaborations, and Other Developments

Adrenocortical carcinoma, also known as adrenal cortex carcinoma, is a rare form of cancer that occurs at the cortex layer of the adrenal gland. There are two adrenal glands present in the human body: one at the top of each kidney. Each adrenal gland is comprised of two distinct structures: the outer part of the adrenal glands (adrenal cortex) and the inner region (adrenal medulla).

Some of the genetic condition that can cause adrenocortical carcinoma are Li-Fraumeni syndrome, Carney complex, and Beckwith-Wiedemann syndrome. Some of the most common symptoms of this medical condition includes abdominal pain, lump in the abdomen, and feeling of fullness. 

Request to Get the Sample Pages at: 

The disease can be diagnosed by imaging technique such as computed tomography (CT) scan, magnetic resonance imaging (MRI), biopsy, blood tests, and urine tests. Millendo Therapeutics Inc. is in the process of developing ATR-101 as an acetyl CoA C-acetyltransferase inhibitor for the treatment of adrenocortical carcinoma. Merck & Co., Inc. is also in the process of developing pembrolizumab as a CD274 antigen inhibitor for the treatment of adrenocortical carcinoma. Some of the other companies and universities having the pipeline drug for adrenocortical carcinoma includes the Columbia University, Medunik Canada Inc., HRA Pharma, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

Cathepsin K Inhibitors Therapeutics - Pipeline Analysis 2019 Clinical Trials & Results

Cathepsin K is a protease enzyme which is coded by CTSK gene. The function associated with the gene involves bone remodelling and resorption. Cathepsin K is a member of peptidase C1 protein family and expressed mainly in osteoclasts. The protein has high specificity for kinins and has the capability to catabolize collagen, elastin, and gelatin. Cathepsin K is found to be over-expressed in cancer such as breast cancer and glioblastoma. The mutation in CTSK gene can cause pycnodysostosis. Due to over expression of cathepsin K in osteoclasts, bone deformation occurs which leads to osteoporosis.

Company like Medivir AB is in the process of developing MIV-711 as a cathepsin K inhibitor for the treatment of osteoarthritis. Amura Holdings Ltd., and Merck & Co. Inc. are some other companies having pipeline of cathepsin K inhibitors.

Request to Get the Sample Pages at:  

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

Adenosine 5-Monophosphate Activated Protein Kinase (AMPK) Modulators Therapeutics - Pipeline Analysis 2018

Adenosine 5-monophosphate activated protein kinase (AMPK) plays an important role in regulation of homeostasis. Dysregulation of AMPK can result in many diseases which includes obesity and type 2 diabetes. Several studies have also suggested that AMPK are also associated with the development of neurological diseases and cancer.

Esperion Therapeutics Inc. is in the process of developing Bempedoic acid as a small molecule which acts as an AMPK stimulant for the treatment of hypercholesterolemia, dyslipidaemia, and hypertension. Betagenon AB, Boehringer Ingelheim International GmbH, and Poxel SA are some other companies having pipeline AMPK modulators for the management of several diseases.

Request to Get the Sample Pages at:  

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

Read More…

Read More

Aurora Kinase Inhibitor Therapeutics - Pipeline Analysis 2019

Aurora kinase are proteins that function as mitotic regulators and are aberrantly expressed in cancerous cells. Aurora kinase inhibitors target these aberrantly expressed regulators, provides genetic stability and prevents tumorigenesis.

Several studies have demonstrated overexpression and amplification of aurora kinase in various haematological and solid cancers. Aurora kinase inhibitors when combined with other anti-cancer agents gives more positive results in variety of cancers. Better evaluation of aurora kinase inhibitors is required which raises the need of biomarkers, effective and novel therapeutic agents. Also, aurora kinase inhibitors selectivity targets cancer cells rather than healthy tissues, providing potential opportunities for more effective drug development with reduced adverse effects.

Request to Get the Sample Pages at: 

AstraZeneca PLC is in the process of developing AZD-2811 as a small molecule which acts as an aurora B inhibitor for the treatment of solid tumors. Some of the other companies having pipeline of aurora kinase inhibitors include AbbVie Inc., Merck & Co., Inc., and CASI Pharmaceuticals Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More…

Read More

Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics - Pipeline Analysis 2019

Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth. Also, studies have demonstrated that HGF inhibitors are significantly more effective than Gemcitabine in inhibiting tumor angiogenesis and metastasis.

Studies have demonstrated that the HGF inhibitor can be a novel therapeutics that can be developed as a monotherapy or as combination therapy with RAS-RAF-MEK, AKT-mTOR, and EGFR inhibitors for the treatment of various human cancers. HGF inhibitors have shown potent antineoplastic effects in several clinical trials for the treatment of head and neck squamous cell carcinoma as HGF/c-Met pathway is directly involved in the development of a proliferative, invasive, and metastatic cancer.

Request to Get the Sample Pages at:   

AVEO Pharmaceuticals Inc. is in the process of developing Ficlatuzumab as a potent HGF inhibitor antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities for the treatment of squamous cell carcinoma of the head and neck and acute myeloid leukemia. Galaxy Biotech LLC, Daiichi Sankyo Company Limited, and Taiho Pharmaceutical Co. are some other companies having HGF inhibitor pipeline.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More...

Read More